---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-329511"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:17:03.794818+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics elects Vikram Karnani as Class II director effective Dec 22, 2025

## Summary
- Vikram Karnani elected to the Board as an independent director; term expires at 2028 Annual Meeting.
- Received option to purchase 59,665 shares at $20.78/share, vesting monthly over three years.
- Will receive annual cash compensation of $45,000 plus standard equity grants under non-employee director plan.
- No family relationships or material transactions with the Company; standard indemnification agreement entered.

## SEC filing metadata
- accession: 0001193125-25-329511
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312525329511/0001193125-25-329511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312525329511/dyn-20251222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-329511
- JSON: https://secwatch.observer/filing/0001193125-25-329511.json
- Plain text: https://secwatch.observer/filing/0001193125-25-329511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.